Evidence map›Paper›PMID 26214688›Full record

ArticlePloS one2015

Infection of Human Liver Myofibroblasts by Hepatitis C Virus: A Direct Mechanism of Liver Fibrosis in Hepatitis C.

Lynda Aoudjehane, Grégoire Bisch, Olivier Scatton, Christelle Granier, Jesintha Gaston, Chantal Housset, Philippe Roingeard, François-Loïc Cosset, Fabiano Perdigao, Pierre Balladur and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Development of an in vitro model to test antifibrotic drugs on primary human liver myofibroblasts.Laboratory investigation; a journal of technical methods and pathology · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 2 countries.

Lynda AoudjehaneSorbonne Universités, UPMC Univ Paris 06, UMR_S 938, CDR Saint-Antoine, F-75005, Paris, France; INSERM, UMR_S 938, CDR Saint-Antoine, F-75012, Paris, France; Human HepCell, Hôpital Saint-Antoine, F-75012 Paris, France.
Grégoire BischHuman HepCell, Hôpital Saint-Antoine, F-75012 Paris, France.
Olivier ScattonSorbonne Universités, UPMC Univ Paris 06, UMR_S 938, CDR Saint-Antoine, F-75005, Paris, France; INSERM, UMR_S 938, CDR Saint-Antoine, F-75012, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Unité de Transplantation Hépatique, F-75013, Paris, France.
Christelle GranierCIRI-International Center for Infectiology Research, Team EVIR, Université de Lyon, Lyon, France; Inserm, U1111, Lyon, France; Ecole Normale Supérieure de Lyon, Lyon, France; Université Lyon 1, Centre International de Recherche en Infectiologie, Lyon, France; CNRS, UMR5308, Lyon, France; LabEx Ecofect, Université de Lyon, Lyon, France.
Jesintha GastonInstitut Cochin, Université Paris Descartes, CNRS (UMR 8104), INSERM U1016, Paris, France.
Chantal HoussetSorbonne Universités, UPMC Univ Paris 06, UMR_S 938, CDR Saint-Antoine, F-75005, Paris, France; INSERM, UMR_S 938, CDR Saint-Antoine, F-75012, Paris, France.
Philippe RoingeardINSERM U966, Université François Rabelais and CHRU de Tours, France.
François-Loïc CossetCIRI-International Center for Infectiology Research, Team EVIR, Université de Lyon, Lyon, France; Inserm, U1111, Lyon, France; Ecole Normale Supérieure de Lyon, Lyon, France; Université Lyon 1, Centre International de Recherche en Infectiologie, Lyon, France; CNRS, UMR5308, Lyon, France; LabEx Ecofect, Université de Lyon, Lyon, France.
Fabiano PerdigaoAP-HP, Hôpital Pitié-Salpêtrière, Unité de Transplantation Hépatique, F-75013, Paris, France.
Pierre BalladurSorbonne Universités, UPMC Univ Paris 06, UMR_S 938, CDR Saint-Antoine, F-75005, Paris, France; INSERM, UMR_S 938, CDR Saint-Antoine, F-75012, Paris, France; AP-HP, Hôpital Saint Antoine, Département de la chirurgie digestive, F-75012, Paris, France.
Takaji WakitaNational Institute of Infectious Diseases, Department of Virology II, Tokyo, Japan.
Yvon CalmusSorbonne Universités, UPMC Univ Paris 06, UMR_S 938, CDR Saint-Antoine, F-75005, Paris, France; INSERM, UMR_S 938, CDR Saint-Antoine, F-75012, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Unité de Transplantation Hépatique, F-75013, Paris, France.
Filomena ContiSorbonne Universités, UPMC Univ Paris 06, UMR_S 938, CDR Saint-Antoine, F-75005, Paris, France; INSERM, UMR_S 938, CDR Saint-Antoine, F-75012, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Unité de Transplantation Hépatique, F-75013, Paris, France.
Assistance Publique – Hôpitaux de Paris · FRSorbonne Université · FRÉcole Normale Supérieure de Lyon · FRInserm · FRInstitut Cochin · FRNational Institute of Infectious Diseases · JPPitié-Salpêtrière Hospital · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic hepatitis C is a major cause of liver fibrosis and cirrhosis. It is generally accepted that inflammation that occurs in response to hepatocyte infection by the hepatitis C virus (HCV) is the main mechanism that triggers myofibroblast differentiation and stimulation in chronic hepatitis C. The aim of this study was to determine if HCV might infect human liver myofibroblasts (HLMF) and directly stimulate their fibrogenic activities.

methodsWe evaluated the expression of the viral entry receptors, levels of HCV-RNA and HCV-protein and the expression of fibrosis markers in HLMF by using quantitative PCR, western blot and immunofluorescence analyses. Pseudoparticles (HCVpp) and cell culture-derived HCV (HCVcc) were used to study the ability of HLMF to support viral entry, replication and fibrosis induction.

resultsWe showed that HLMF expressed all known molecules of the HCV receptor complex, i.e. CD81, LDL-R, scavenger receptor-BI, claudin-1 and occludin. These cells were also permissive to HCVpp entry. Inoculation with HCVcc caused short-term infection of these cells, as shown by their content in positive- and negative-strand HCV RNA, in core and NS3 viral proteins, and by their release of core protein levels in the culture supernatants. HCV infection stimulated myofibroblastic differentiation, proliferation and collagen production in these cells. In addition, evidence of in vivo infection was provided by the detection of positive- and negative-strand HCV RNA in preparations of HLMF obtained from HCV-infected patients.

conclusionThese findings indicate that HCV infection of HLMF can occur and trigger extracellular matrix overproduction, thereby contributing to the development of HCV-related liver fibrosis.

Indexed as

Hepatitis C, ChronicLiverLiver CirrhosisMyofibroblastsAgedClaudin-1DEAD-box RNA HelicasesFemaleHepacivirusHumansMaleMiddle AgedNucleoside-TriphosphataseOccludinReceptors, LDLRNA, ViralCD81 protein, humanClaudin-1CLDN1 protein, humanDEAD-box RNA HelicasesLDLR protein, humanNS3 protein, hepatitis C virusNucleoside-TriphosphataseOccludinOCLN protein, humanReceptors, LDLRNA, ViralSCARB1 protein, humanScavenger Receptors, Class BSerine EndopeptidasesTetraspanin 28Viral Nonstructural ProteinsViral Proteases

Identifiers

PMID26214688
PMCPMC4516308
OpenAlexW1863236859

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.